

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)

ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD) FOR THE SIX MONTHS ENDED 30 JUNE 2017

Reference is made to the overseas regulatory announcement dated 22 August 2017 (the “**Announcement**”) and issued by Sinopharm Group Co. Ltd. (the “**Company**”) in relation to the summary of the interim report for the six months ended 30 June 2017 of China National Medicines Corporation Ltd. (“**SINOPHARM (CNCM LTD)**”), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of SINOPHARM (CNCM LTD) for the six months ended 30 June 2017 as set out in the Announcement.

**PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM
(CNCMLTD)**

Unit: Yuan
Currency: RMB

Principal Accounting Data	The reporting period (January to June)	The corresponding period of last year	Increase/decrease during the reporting period as compared to the corresponding period of last year (%)
Operating Revenue	17,604,079,391.61	16,674,577,196.06	5.57
Net profit attributable to shareholders of the listed company	553,888,940.14	499,840,934.58	10.81
Net profit attributable to shareholders of the listed company net of non-recurring gain or loss	454,738,147.42	288,173,133.23	57.80
Net cash flows from operating activities	-469,572,790.34	658,396,632.53	-171.32
	As at the end of the reporting period	As at the end of last year	Increase/decrease at the end of the reporting period as compared to the end of last year (%)
Net assets attributable to shareholders of the listed company	7,607,779,578.32	5,849,499,679.02	30.06
Total assets	18,351,952,677.18	16,665,541,979.54	10.12
Principal Financial Indicators	The reporting period (January to June)	The corresponding period of last year	Increase/decrease during the reporting period as compared to the corresponding period of last year (%)
Basic earnings per share (RMB/Share)	0.7851	0.7210	8.89
Diluted earnings per share (RMB/Share)	0.7851	0.7210	8.89
Weighted average return on net assets (%)	8.78	9.67	Decreased by 0.89

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
Sinopharm Group Co. Ltd.
Li Zhiming
Chairman

Shanghai, the PRC
22 August 2017

As at the date of this announcement, the executive director of the Company is Mr. Li Zhiming; the non-executive directors of the Company are Mr. Chen Qi Yu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Ma Ping, Mr. Deng Jindong, Mr. Li Dongjiu, Mr. Lian Wanyong and Mr. Wu Yijian; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong and Mr. Zhuo Fumin.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."*